OKYO Pharma Files Annual Report, $20.6M Cash to Fund Phase 3 NEPTUNE Trial
OKYO is trading near its 52-week low of $1.34 (7.5% above the low) on light trading volume (0.4× avg).
Summary
OKYO Pharma filed its 20-F annual report, revealing a net loss of $8.9M for FY2026 and a cash position of $20.6M as of March 2026. The company says this is enough to fully fund the upcoming Phase 3 NEPTUNE trial for urcosimod in neuropathic corneal pain, which is set to start in the second half of 2026. The trial design, enrolling 111 patients, follows positive FDA feedback from a Type D meeting earlier this month. The cash runway through a pivotal readout removes a key overhang for this micro-cap biotech. The next catalyst is the actual trial initiation, expected in the coming months.
At the time of this announcement, OKYO was trading at $1.44 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $73.5M. The 52-week trading range was $1.34 to $3.35. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.